TLRY Earnings Test: EBITDA Growth Must Become Cash Flow
Tilray Brands’ (NASDAQ: TLRY) fiscal 2026 earnings establish a clear but demanding setup for fiscal 2027: management has put forward an EBITDA-growth framework, while the equity case still depends on whether that progress can be converted into durable free cash flow without further material per-share pressure. For cannabis investors, the distinction matters. In a sector where regulatory optionality can dominate the narrative, Tilray’s filings offer a more concrete underwriting question: can a diversified cannabis, distribution and beverage platform move from adjusted earnings growth to cash generation?
The latest tape reinforces why fundamentals matter more than isolated share-price moves. TLRY was down 2.9% to $4.02, while U.S. MSO proxy exposure was also softer: MSOS declined 1.66% to $4.75, MSOX fell 4.76% to $2.80, GTBIF declined 3.2% to $7.25, CURLF fell 2.54% to $9.58, and CRLBF declined 2.3% to $0.71. Those movements do not establish a sector-wide fundamental conclusion on their own, but they do show that public-cannabis capital remains selective, risk-sensitive, and unwilling to grant automatic credit for adjusted-profit metrics.
The earnings thesis: guidance is constructive, cash flow is decisive
Tilray’s fiscal 2026 release, filed as SEC Exhibit 99.1, reported $915.454 million in net revenue and $61.139 million in adjusted EBITDA. The same filing set fiscal 2027 adjusted EBITDA guidance at $68 million to $75 million and said the company expects annual revenue of more than $1 billion. That is a constructive operating outlook: management is signaling both continued scale and incremental adjusted-EBITDA improvement.
The key qualification is equally clear. Fiscal 2026 free cash flow was negative $98.624 million. That fact should frame the earnings analysis more than the headline revenue threshold. Revenue growth is strategically useful, particularly for a company operating across cannabis, distribution and beverage activities. Adjusted EBITDA growth can be an important indication of operational leverage. Neither metric, however, substitutes for cash conversion when the enterprise is still consuming meaningful cash.
Investors should therefore treat the fiscal 2027 guide as an operational checkpoint rather than a complete equity thesis. Delivering within the $68 million to $75 million range would demonstrate that the company can expand adjusted EBITDA. It would not by itself demonstrate that the business is self-funding, that capital intensity has normalized, or that future growth can be financed without a potentially unfavorable impact on existing shareholders.
That distinction is not semantic. In cannabis equities, the gap between adjusted EBITDA and free cash flow is often where valuation narratives become fragile. Tilray’s own reported fiscal 2026 figures make that gap visible. The appropriate question is not simply whether EBITDA rises from $61.139 million; it is whether cash consumption materially improves as EBITDA rises.
The primary filing is the starting point for that assessment: Tilray’s fiscal 2026 earnings release filed as SEC Exhibit 99.1.
What the guide does—and does not—tell the market
Management’s fiscal 2027 framework provides an earnings direction, but it does not provide a documented reconciliation from adjusted EBITDA to GAAP operating income or free cash flow. That absence does not invalidate the guidance. It does mean investors should be disciplined about what the guidance can support.
A base-case read-through is straightforward: Tilray delivers adjusted EBITDA within the $68 million to $75 million range, revenue progresses toward the company’s stated more-than-$1 billion expectation, and cash usage improves without yet proving positive free cash flow. That would validate the company’s diversified-platform strategy at the operating level, while leaving the valuation debate unresolved.
A more favorable outcome would require more than exceeding the upper end of the guide. It would require evidence that growth in international medical cannabis, distribution and beverage operations is translating into free-cash-flow improvement, and that the company can finance growth without material dilution. By contrast, a weaker outcome would be EBITDA below the $68 million guide floor alongside continued material cash outflow and a larger share count.
This is why the earnings debate should remain grounded in the cash-flow statement and the balance sheet rather than in revenue scale alone. Tilray’s fiscal 2026 release supports a credible growth discussion. It does not yet support a conclusion that the equity has crossed into a cash-generative phase.
Balance-sheet capacity is real, but per-share execution matters
At May 31, 2026, Tilray reported $225.977 million of cash and cash equivalents and $5.289 million of marketable securities. It also reported $8.775 million of bank indebtedness, $138.585 million of current and long-term debt, and $79.529 million of convertible debentures.
This liquidity profile gives Tilray capacity to execute its strategy, but capacity is not equivalent to a clean capital structure. Investors assessing the fiscal 2027 earnings path should follow liquidity alongside outstanding shares, debt obligations, convertibles, and cash flow. The balance-sheet question is not whether Tilray has resources today; its filing indicates that it does. The more consequential question is whether those resources can support operating expansion while preserving or improving per-share economics.
The reported common-share count makes that issue tangible. Tilray had 131,683,075 common shares issued and outstanding at May 31, 2026, compared with 106,067,875 one year earlier after retrospective adjustment for the reverse split. That change does not, by itself, establish that every increment was value-destructive. It does establish why investors should assess future earnings progress on a per-share and cash-flow basis, not just on absolute adjusted EBITDA.
The fiscal 2026 release is the relevant primary record for both liquidity and the share-count comparison: Tilray’s reported balance-sheet and share data.
BrewDog makes TLRY a global execution story
Tilray is not solely a U.S. cannabis-policy vehicle. Its fiscal 2026 acquisition of BrewDog and broader beverage strategy make the company’s earnings model explicitly international. Tilray described the acquisition as supporting a pro forma global beverage platform of approximately $500 million. Its earlier fiscal third-quarter release described an acquisition price of approximately £40 million in cash and a Carlsberg partnership beginning in 2027.
That is the central non-U.S. angle in the Tilray story: the prospective earnings bridge is not dependent exclusively on U.S. federal reform or domestic cannabis pricing. A global beverage platform can diversify revenue sources and potentially give the company additional routes to scale. It can also introduce execution complexity, integration risk, and the need to demonstrate that acquisitions create cash-flow capacity rather than merely a larger reported revenue base.
For investors comparing Tilray with U.S.-focused exposures such as GTBIF, CURLF, and CRLBF, the differentiation is strategic rather than automatically financial. Tilray’s international diversification may broaden its addressable operating footprint. But until segment-level profitability, acquisition accounting, synergies, and cash-flow contributions are more fully demonstrated, diversification should be treated as a potential advantage—not as confirmed earnings accretion.
The disclosure underpinning the BrewDog discussion is available in Tilray’s fiscal third-quarter earnings release filed with the SEC.
U.S. rescheduling remains upside optionality, not the core model
Federal policy remains relevant to the cannabis-equity complex, but investors should resist embedding a definitive regulatory result into near-term earnings expectations. The DEA marijuana-rescheduling hearing occurred from June 29 through July 15, 2026, and the administrative law judge set August 17, 2026 as the deadline for proposed transcript corrections and post-hearing briefs. The timing and substance of a subsequent decision were not established in the available record.
That creates asymmetry: a favorable regulatory development could improve sentiment across TLRY, MSOS, GTBIF, CURLF, and CRLBF, while a delay or outcome that does not materially benefit Tilray’s addressable market would leave operating execution as the primary valuation driver. The important analytical discipline is to separate policy optionality from disclosed earnings capacity.
Tilray’s fiscal 2026 Form 10-K also underscores that it faces significant competition across cannabis and beverage businesses, including illicit-market participants and large, well-capitalized competitors. In other words, policy progress would not remove the competitive and execution hurdles that determine whether EBITDA converts into cash.
The procedural record is available in the DEA order on transcript corrections and post-hearing briefs, while Tilray’s competitive-risk disclosure appears in its fiscal 2026 Form 10-K.
What we’d watch
First, watch whether TLRY delivers fiscal 2027 adjusted EBITDA within its $68 million to $75 million guide range. Second, watch whether free cash flow improves materially from the fiscal 2026 outflow of $98.624 million. Third, watch the common-share count against the 131,683,075 reported at fiscal year-end. Fourth, watch for disclosure that quantifies BrewDog profitability, cash-flow contribution, integration progress, or a credible bridge from adjusted EBITDA to free cash flow.
The principal risks are explicit: persistent negative free cash flow, additional dilution, acquisition-integration shortfalls, competitive pressure across cannabis and beverages, and regulatory timing that fails to produce a material operating benefit. These are not peripheral considerations. They are the variables that determine whether Tilray’s forecast operating progress becomes durable equity economics.
Bottom line
Tilray’s fiscal 2026 results provide a credible earnings-growth framework: $915.454 million of revenue, $61.139 million of adjusted EBITDA, and fiscal 2027 guidance of $68 million to $75 million in adjusted EBITDA alongside expected revenue above $1 billion. The limiting factor is cash conversion. With fiscal 2026 free cash flow at negative $98.624 million and shares outstanding at 131,683,075, the next phase of the story is not simply about delivering higher adjusted EBITDA.
Our lean is to view TLRY as a cash-conversion and execution watchlist exposure rather than a pure regulatory-beta expression. The most important confirmation would be a narrowing of the gap between adjusted EBITDA and free cash flow, supported by disciplined capital allocation and demonstrable contribution from the global beverage platform.